(Q33751191)

English

Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19889613%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19889613%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference

based on heuristic

inferred from title

François Radvanyi

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19889613%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

author name string

M Laé

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19889613%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

J Couturier

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19889613%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

S Oudard

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19889613%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

P Beuzeboc

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19889613%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

A Vieillefond

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19889613%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

publication date

4 November 2009

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19889613%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Annals of Oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19889613%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

21

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19889613%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

815-819

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19889613%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19889613%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844947

14 July 2018

Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844947

14 July 2018

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844947

14 July 2018

Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844947

14 July 2018

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844947

14 July 2018

HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844947

14 July 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844947

14 July 2018

Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844947

14 July 2018

C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844947

14 July 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844947

14 July 2018

Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP488

21 January 2018

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP488

21 January 2018

HER-2 testing in breast cancer using parallel tissue-based methods.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP488

21 January 2018

HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy?

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP488

21 January 2018

HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP488

21 January 2018

No strong association between HER-2/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinomas.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP488

21 January 2018

Confrontation of immunohistochemistry and fluorescent in situ hybridization for the assessment of HER-2/ neu (c-erbb-2) status in urothelial carcinoma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP488

21 January 2018

Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP488

21 January 2018

A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP488

21 January 2018

C-ERBB-2 gene amplification as a prognostic marker in human bladder cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19889613

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19889613

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/19889613

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process

1 reference

https://pubmed.ncbi.nlm.nih.gov/19889613

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome

1 reference

https://pubmed.ncbi.nlm.nih.gov/19889613

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19889613

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trastuzumab (Herceptin) in metastatic transitional cell carcinoma of the urinary tract: report on six patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19889613

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19889613

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Potential for HER-2/neu molecular targeted therapy for invasive bladder carcinoma: comparative study of immunohistochemistry and fluorescent in situ hybridization

1 reference

https://pubmed.ncbi.nlm.nih.gov/19889613

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical importance of HER2 immunohistologic heterogeneous expression in core-needle biopsies vs resection specimens for equivocal (immunohistochemical score 2+) cases

1 reference

https://pubmed.ncbi.nlm.nih.gov/19889613

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER2 overexpression and amplification in urothelial carcinoma of the bladder is associated with MYC coamplification in a subset of cases

1 reference

https://pubmed.ncbi.nlm.nih.gov/19889613

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/ANNONC/MDP488

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19889613%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19889613%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19889613%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33751191&oldid=1973869154"